Biomea Fusion, Inc. Cash and Cash Equivalents
Biomea Fusion, Inc. (BMEA) had Cash and Cash Equivalents of $34.82 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-05
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $34.82M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $44.69M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $55.81M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $46.64M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $34.82M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $44.69M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $55.81M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $46.64M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $56.22M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $35.86M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $58.28M 10-K · filed 2026-03-24 |
| 2024-09-30 | $87.95M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $113.29M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $144.92M 10-Q · filed 2025-05-05 |
| 2023-12-31 | $176.87M 10-K · filed 2026-03-24 |
| 2023-09-30 | $199.09M 10-Q · filed 2024-10-29 |
| 2023-06-30 | $222.91M 10-Q · filed 2024-07-31 |
| 2023-03-31 | $86.30M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $111.90M 10-K · filed 2025-03-31 |
| 2022-09-30 | $132.31M 10-Q · filed 2023-10-30 |
| 2022-06-30 | $148.48M 10-Q · filed 2023-07-31 |
| 2022-03-31 | $156.22M 10-Q · filed 2023-05-02 |
| 2021-12-31 | $145.74M 10-K · filed 2024-03-28 |
| 2021-09-30 | $156.97M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $166.04M 10-Q · filed 2022-08-01 |
| 2021-03-31 | $18.89M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $61.70M 10-K · filed 2023-03-28 |
| 2020-09-30 | $8.08M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $9.20M 10-Q · filed 2021-08-11 |
| 2020-03-31 | $37.00K 10-Q · filed 2021-05-27 |
| 2019-12-31 | $239.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |